Hydralazine
Mostrando 13-24 de 51 artigos, teses e dissertações.
-
13. Hydralazine prevents nitroglycerin tolerance by inhibiting activation of a membrane-bound NADH oxidase. A new action for an old drug.
Hydralazine has been shown to reduce mortality in patients with congestive heart failure when given concomitantly with isosorbide dinitrate. Recently, we demonstrated that nitrate tolerance is in part due to enhanced vascular superoxide .O2- production. We sought to determine mechanisms whereby hydralazine may prevent tolerance. Rabbits either received no tr
-
14. Comparison of haemodynamic effects of oral hydralazine and prazosin hydrochloride in patients with chronic congestive heart failure.
The comparative haemodynamic effects of oral prazosin hydrochloride and hydralazine were evaluated in 11 patients with chronic congestive heart failure. The maximum total dose of prazosin received by an individual varied up to 25 mg. Ten patients received a maximum of 75 mg and one received 50 mg of hydralazine at six-hour intervals. There was no significant
-
15. Comparison of haemodynamic effects of oral prazosin, oral hydralazine, and intravenous nitroprusside in same patients with chronic heart failure.
The haemodynamic effects of oral prazosin and hydralazine were evaluated in patients with refractory heart failure and compared with those of intravenous nitroprusside in the same patients. Both oral agents were well tolerated and appeared to have beneficial haemodynamic effects. Prazosin and hydralazine produced similar increases in cardiac output associate
-
16. Haemodynamic response to intravenous hydralazine in patients with pulmonary hypertension.
The acute pulmonary and systemic haemodynamic response to low (0.15 mg/kg) and high (0.30 mg/kg) doses of intravenous hydralazine was evaluated in 26 consecutive patients with severe pulmonary hypertension due to cor pulmonale (nine patients), primary pulmonary hypertension (11 patients), or pulmonary embolism (six patients). Hydralazine did not cause a sign
-
17. Influence of Prostaglandin Synthesis Inhibitors on Pulmonary Vasodilatory Effects of Hydralazine in Dogs with Hypoxic Pulmonary Vasoconstriction
To determine whether hydralazine, a systemic vasodilator, exerted a similar effect on the pulmonary circulation, we studied the circulatory changes in dogs during three interventions: (a) the control state during room air ventilation; (b) during continuous hypoxic ventilation with 10% oxygen, and maintaining continuous hypoxic ventilation; and (c) after 1 mg
-
18. Comparative electrophysiological effects of captopril or hydralazine combined with nitrate in patients with left ventricular dysfunction and inducible ventricular tachycardia.
OBJECTIVE--To assess the electrophysiological and antiarrhythmic effects of pharmacological load manipulation by an angiotensin converting enzyme (ACE) inhibitor (captopril) and a direct vasodilator (hydralazine plus isosorbide mononitrate) in patients with inducible ventricular tachycardia and impaired left ventricular function. DESIGN--Randomised open labe
-
19. Hydralazine for treatment of severe hypertension in pregnancy: meta-analysis
Objective To review outcomes in randomised controlled trials comparing hydralazine against other antihypertensives for severe hypertension in pregnancy.
BMJ Publishing Group Ltd..
-
20. Vasodilator treatment with isosorbide dinitrate and hydralazine in chronic heart failure.
Several reports have suggested that because isosorbide dinitrate and hydralazine have different and additive haemodynamic effects at rest in patients with chronic heart failure, these agents should be administered in combination. Some studies, however, indicate thay they are effective individually as well. Since most patients with heart failure are symptomat
-
21. Afterload reduction treatment for large ventricular septal defects. Dependence of haemodynamic effects of hydralazine on pretreatment systemic blood flow.
The haemodynamic effects of hydralazine were studied in seven infants and a child, each with a large ventricular septal defect. Hydralazine, 0.3 mg/kg, was administered intravenously. This caused a lowering of pulmonary arterial pressure from 57 +/- 4 mmHg to 49 +/- 4 mmHg, and a lowering of left atrial pressure from 12 +/- 1 mmHg to 10 +/- 1 mmHg. Systemic
-
22. Pulmonary hypertension in hydralazine induced systemic lupus erythematosus: association with C4 null allele.
A patient who developed pulmonary hypertension and systemic lupus erythematosus as a complication of hydralazine therapy is reported. She was a slow acetylator and in addition was found to have a null allele at the C4A locus.
-
23. Occupational asthma in a pharmaceutical worker exposed to hydralazine.
A pharmaceutical worker developed asthma when exposed to hydralazine, an antihypertensive drug. The diagnosis of occupational asthma was supported by specific inhalation challenges, which produced a late asthmatic reaction and an increase in bronchial responsiveness. No evidence of an IgE or an IgG dependent mechanism could be found.
-
24. Haemodynamic effects of hydralazine at rest and during exercise in patients with chronic heart failure.
The administration of vasodilator drugs has been shown to have beneficial effects at rest in patients with acute or chronic heart failure. To determine the efficacy of hydralazine during exercise, 10 severely symptomatic patients with chronic left ventricular failure from diffuse coronary disease or cardiomyopathy were studied at rest and during upright exer